Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quartette
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quartette (DR-103) is an extended-cycle oral contraceptive developed by Teva Women's Health. It consists of a 91-day regimen of ethinyl estradiol and levonorgestrel. Unlike traditional 91-day regimens that use a constant dose of estrogen, Quartette features an ascending dose of ethinyl estradiol (20 mcg, 25 mcg, and 30 mcg) combined with a constant dose of levonorgestrel (150 mcg) for 84 days, followed by 7 days of 10 mcg ethinyl estradiol. This design is intended to reduce breakthrough bleeding, a common issue with extended-cycle contraceptives. It was approved by the FDA in 2013 for the prevention of pregnancy.
- Brand names
- Quartette
- Other names
- ethinyl estradiol + levonorgestrelregorafenib + TAS-102-Teva Women's Health-pregnancy
02
Targets
PR (Progesterone receptor)ER (Estrogen receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on Quartette.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quartette.